Because the medication slows digestion, fatty foods sit in the stomach longer and are the number one trigger for severe nausea and vomiting, she explains
Some patients notice visible changes to their weight by the end of the first or third month, while others experience more gradual, significant weight loss after six months
On April 6, the phase III TRANSCEND study results showed that the MC4R agonist setmelanotide reduced the BMI of these patients by an average of 19.8%, offering a promising new treatment option for this group of patients
Wegovy commonly causes nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation
Gradual dose escalation helps the body adjust to treatment